title: Personalized peptide vaccination for advanced colorectal cancer.
abstract: We have developed a novel approach in cancer immunotherapy, the personalized peptide vaccination (PPV), in which human leukocyte antigen (HLA)-matched peptides are selected on the basis of preexisting host immunity before vaccination. Recently, we demonstrated the feasibility of PPV in previously treated patients with advanced colorectal cancer, thus warranting further clinical development of this approach.
authors.affiliation: Cancer Vaccine Center; Kurume University ; Kurume, Japan ; Cancer Vaccine Center; Kanagawa Cancer Center Research Institute ; Yokohama, Japan.
authors.forename: Tetsuro
authors.initials: T
authors.lastname: Sasada
authors.affiliation: Department of Surgery; Kurume University School of Medicine ; Kurume, Japan.
authors.forename: Shiro
authors.initials: S
authors.lastname: Kibe
authors.affiliation: Department of Surgery; Kurume University School of Medicine ; Kurume, Japan.
authors.forename: Yoshito
authors.initials: Y
authors.lastname: Akagi
authors.affiliation: Cancer Vaccine Center; Kurume University ; Kurume, Japan.
authors.forename: Kyogo
authors.initials: K
authors.lastname: Itoh
keywords: CTL, cytotoxic T lymphocyte; HR, hazard ratio; IL-6; OS, overall survival; PPV, personalized peptide vaccination.; aCRC, advanced colorectal cancer; biomarker; colorectal cancer; peptide vaccine; personalized vaccine